防治糖皮质激素性骨折一线与二线药物的疗效与安全性
该网络荟萃分析纳入19项随机对照试验共4328例长期使用糖皮质激素的患者,比较一线与二线药物预防糖皮质激素性骨折的疗效与安全性。结果显示特立帕肽、地舒单抗和利塞膦酸可降低椎体骨折风险,特立帕肽和地舒单抗疗效最优;口服阿仑膦酸在每日≥7.5 mg患者中有效,静脉伊班膦酸对原发预防有效。
要点
- 特立帕肽、地舒单抗和利塞膦酸可降低糖皮质激素性椎体骨折风险。
- 特立帕肽和地舒单抗在降低椎体骨折风险上疗效最优。
- 口服阿仑膦酸对每日泼尼松≥7.5 mg患者可降低椎体骨折风险。
核心结论
- 在临床疗效和安全性方面,二线药物特立帕肽和地舒单抗对一线口服双膦酸盐预防糖皮质激素性骨折构成挑战。
研究设计与样本
- 系统检索3个数据库至2019年3月5日,纳入19项独特随机对照试验共4328例长期使用糖皮质激素的患者。
- 采用多变量随机效应网络荟萃分析,包括基础分析、3个亚组分析和12项敏感性分析。
主要发现
- 特立帕肽(RR 0.11,95%CI 0.03-0.47)、地舒单抗(RR 0.21,95%CI 0.09-0.49)和利塞膦酸(RR 0.33,95%CI 0.19-0.58)降低糖皮质激素性椎体骨折风险。
- 根据包括累积排名曲线下面积值的小提琴图,特立帕肽和地舒单抗在基础和敏感性分析中疗效最优。
- 口服阿仑膦酸(RR 0.33,95%CI 0.12-0.93)在每日接受至少7.5 mg糖皮质激素的患者中降低椎体骨折风险。
- 静脉伊班膦酸(RR 0.25,95%CI 0.06-0.99)对糖皮质激素性骨质疏松的原发预防有效。
- 六种药物在其余5项结局方面表现相似。
临床怎么用
- 对于长期使用糖皮质激素的患者,可考虑特立帕肽或地舒单抗作为预防椎体骨折的优选方案。
- 口服阿仑膦酸可用于每日泼尼松≥7.5 mg患者的椎体骨折预防。
- 静脉伊班膦酸可用于糖皮质激素性骨质疏松的原发预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The evidence about benefits and harms of drugs for glucocorticoid (GC)-induced osteoporosis (GIOP) is limited, and the comparative efficacy and safety of first-line and second-line agents to prevent GC-induced (GI) fractures remains unclear. OBJECTIVE: To assess the comparative clinical efficacy, safety, and tolerability of first-line and second-line agents in preventing GI fractures. DATA SOURCES: We searched 3 different databases through March 5, 2019. STUDY SELECTION: We included randomized controlled trials enrolling patients receiving long-term GCs and compared a first-line and second-line agent with one another and with placebo. DATA EXTRACTION: Two reviewers independently extracted study and participant characteristics and outcome data. DATA SYNTHESIS: We performed multivariate random-effects network meta-analyses including base, 3 subgroups, and 12 sensitivity analyses. We included 22 papers from 19 unique trials involving 4328 patients receiving GCs. Teriparatide (risk ratio [RR] 0.11, 95% confidence interval [CI] 0.03-0.47), denosumab (RR 0.21, 95% CI 0.09-0.49), and risedronate (RR 0.33, 95% CI 0.19-0.58) reduced the risk of GI vertebral fractures, and the former 2 were the most efficacious according to violin plots including the surface under the cumulative ranking curve values calculated by base and sensitivity analyses. Oral alendronate (RR 0.33, 95% CI 0.12-0.93) reduced this risk in patients receiving GCs with at least 7.5 mg/day, while intravenous ibandronate (RR 0.25, 95% CI 0.06-0.99) was efficacious for the primary prevention of GIOP. Six drugs were similar in terms of the 5 other outcomes. CONCLUSIONS: In terms of clinical efficacy and safety, second-line teriparatide and denosumab pose a challenge to first-line oral bisphosphonates for prevention of GI fractures.
引用
- Ding L, Hu J, Wang D, et al. Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures. J Clin Endocrinol Metab. 2020. PMID: 31513250. doi:10.1210/clinem/dgz023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。